CJC+IPA (noDAC)
25% off when buying 10+ items (any product)
CJC-1295 + Ipamorelin | Peptide Complex
Growth Hormone
CJC-1295 + Ipamorelin is a synergistic combination of two complementary growth hormone-stimulating peptides that work through distinct but complementary receptor pathways to maximize pulsatile GH secretion. CJC-1295 is a GHRH (Growth Hormone Releasing Hormone) analogue that binds to GHRH receptors on pituitary somatotrophs, while Ipamorelin activates ghrelin receptors to amplify GH pulse amplitude. Together, they produce a potent, synergistic increase in GH output that exceeds either compound used alone — establishing this combination as one of the most researched GH optimization protocols in peptide science.
Synergistic GH Release — CJC-1295 and Ipamorelin act on different pituitary receptors (GHRH-R and GHSR respectively), producing additive to synergistic increases in GH pulse amplitude that significantly exceed either compound alone in research models.
Extended Half-Life — CJC-1295 with DAC (Drug Affinity Complex) binds to serum albumin, extending its half-life to 6–8 days, allowing sustained GHRH signaling between dosing intervals in pharmacokinetic research.
IGF-1 Elevation — The combination produces sustained IGF-1 elevation over time, supporting research into anabolic signaling, tissue repair, and metabolic optimization through the GH/IGF-1 axis.
Body Composition & Recovery — Research into this combination consistently demonstrates effects on lean mass preservation, adipose tissue reduction, and recovery capacity through GH-mediated metabolic and anabolic pathways.
Selective & Clean Profile — The addition of Ipamorelin maintains selectivity for GH release without significant cortisol or prolactin elevation, preserving the favorable hormonal environment of pulsatile GH stimulation in research subjects.
){kind=link}